Literature DB >> 11163360

SRC transcriptional activation in a subset of human colon cancer cell lines.

S Dehm1, M A Senger, K Bonham.   

Abstract

Human SRC encodes the non-receptor tyrosine kinase pp60(c-Src), which is activated in many human colon cancer cell lines (HCCLs) and tumors. We found that both c-Src protein and mRNA levels were elevated in a subset of HCCLs. Increased c-Src mRNA and protein levels correlated strongly with increased c-Src kinase activity. Nuclear run-on analysis and c-Src mRNA half-life determination demonstrated increased mRNA levels were due to increased transcription of the SRC gene. We also observed decreased c-Src mRNA stability in cell lines that displayed SRC transcriptional activation. Our findings provide the first evidence that SRC transcriptional activation is an important determinant of c-Src expression and activity in HCCLs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163360     DOI: 10.1016/s0014-5793(00)02354-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Expression, purification, and bioactivity of GST-fused v-Src from a bacterial expression system.

Authors:  Xing-Guo Gong; Jing Ji; Jie Xie; Yuan Zhou; Jun-Yan Zhang; Wen-Tao Zhong
Journal:  J Zhejiang Univ Sci B       Date:  2006-01       Impact factor: 3.066

2.  c-src activating mutation analysis in Chinese patients with colorectal cancer.

Authors:  Ye-Xiong Tan; Han-Tao Wang; Peng Zhang; Zhong-Hua Yan; Guan-Long Dai; Meng-Chao Wu; Hong-Yang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

3.  Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.

Authors:  Audrey Sirvent; Oana Vigy; Beatrice Orsetti; Serge Urbach; Serge Roche
Journal:  Mol Cell Proteomics       Date:  2012-09-29       Impact factor: 5.911

4.  Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.

Authors:  Arkadiusz Welman; Christopher Cawthorne; Lourdes Ponce-Perez; Jane Barraclough; Sarah Danson; Stephen Murray; Jeff Cummings; Terry D Allen; Caroline Dive
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

5.  Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.

Authors:  Christopher J Morrow; Mohammad Ghattas; Christopher Smith; Heinz Bönisch; Richard A Bryce; D Mark Hickinson; Tim P Green; Caroline Dive
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

6.  Restriction of Src activity by Cullin-5.

Authors:  George S Laszlo; Jonathan A Cooper
Journal:  Curr Biol       Date:  2009-01-15       Impact factor: 10.834

7.  SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors.

Authors:  Scott M Dehm; Traci L Hilton; Edith H Wang; Keith Bonham
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 8.  Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

Authors:  John de Groot; Vanessa Milano
Journal:  J Neurooncol       Date:  2009-05-13       Impact factor: 4.130

9.  Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.

Authors:  Audrey Sirvent; Christine Benistant; Serge Roche
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

10.  Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.

Authors:  Dhananjay P Kunte; Ramesh K Wali; Jennifer L Koetsier; Hemant K Roy
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.